3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Status
Recruiting
8
Active not recruiting
3
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
3
Conditions
Prostatic Neoplasms
2
Metastatic Castration-resistant Prostate Cancer
1
Interventions
Specimen Handling
111
Magnetic Resonance Spectroscopy
88
Carboplatin
58
pembrolizumab
57
Biopsy
56
Cisplatin
51
Nivolumab
46
Paclitaxel
39
Radiotherapy
38
Cyclophosphamide
38
Gemcitabine
33
Dexamethasone
31
Radiation
30
Bevacizumab
30
atezolizumab
27
Pemetrexed
27
Etoposide
27
olaparib
24
Lenalidomide
24
Doxorubicin
23
X-Rays
22
Vincristine
22
Prednisone
22
Leucovorin
22
Immunoglobulin G
22
Docetaxel
22
Disulfides
22
venetoclax
21
durvalumab
21
Rituximab
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Active not recruiting
×
Pluvicto
×
30 days
×
Clear all
NCT04720157
2026-05-27
PSMAddition
Novartis
Phase 3
Active not recruiting
1,140 enrolled
NCT05849298
2026-05-27
PSMACare
Novartis
Phase 2
Active not recruiting
49 enrolled
NCT05682443
2026-05-22
PRESERVE-006
OncoC4, Inc.
Phase 1/2
Active not recruiting
148 enrolled